- Tytuł:
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
- Autorzy:
- Temat:
-
CROHN'S disease
INFLAMMATORY bowel disease treatment
INTERLEUKIN-23
THERAPEUTIC use of monoclonal antibodies
TUMOR necrosis factors
PATIENTS
COMPARATIVE studies
DRUG administration
DOSE-effect relationship in pharmacology
GASTROINTESTINAL agents
INTERLEUKINS
RESEARCH methodology
MEDICAL cooperation
MONOCLONAL antibodies
RESEARCH
STATISTICAL sampling
EVALUATION research
RANDOMIZED controlled trials
TREATMENT effectiveness
DISEASE remission
BLIND experiment
SEVERITY of illness index
CHEMICAL inhibitors
THERAPEUTICS - Źródło:
- Lancet. 4/29/2017, Vol. 389 Issue 10080, p1699-1709. 11p.
Czasopismo naukowe